drugset
drugset / Trial / NCT04640532

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

NCT04640532 ↗

Phase 1/2 Unknown 116 enrolled Kartos Therapeutics, Inc. Telios Pharma, Inc. · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Timeline

Start
2020-11-17
Primary completion
2022-05-11
Completion
2025-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Navtemadlin Small molecule 240 mg Oral
Subject TL-895 Small molecule 100 mg Oral
Subject TL-895 Small molecule 150 mg Oral
Subject TL-895 Small molecule 200 mg Oral
Subject TL-895 Small molecule 300 mg Oral

Indications

myelofibrosis primary myelofibrosis